A Phase 3 interventional study of EP2006 and Filgrastim in Chemotherapy Associated Neutropenia and Breast Cancer, sponsored by Sandoz. Completed at 26 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-06.
Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing filgrastim in Breast Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Filgrastim · Breast Neoplasms.
Among the 31 studies testing filgrastim in Breast Neoplasms, this one is the 10th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2011, is one of 7 in phase 3, and was the 23rd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →1 of the 31 studies testing filgrastim in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
By country, each count listing its studies:
Filgrastim: first FDA approval 1991 (NEUPOGEN), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 15 · Phase 3 7 · Phase 4 5
First in 1995; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 218 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 120 across the 27 interventional studies. Of the 29 that completed or were terminated, 10 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sandoz, one of the names counted as Novartis. Under that name alone:
Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 53rd largest by enrollment of the 155 interventional ones that give a count, is one of 4 that started in 2011, is one of 45 in phase 3, and was the 80th registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 31 studies testing filgrastim in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The study will assess the efficacy of EP2006 compared to Filgrastim with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible patients will be teated with EP2006
Drug: EP2006
Eligible patients will be teated with Filgrastim
Drug: Filgrastim
Eligible patients will be teated with EP2006
Also known as: Filgrastim
Eligible patients will be teated with Filgrastim
Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy
Mean duration of severe neutropenia, defined as the mean number of consecutive days with Grade 4 neutropenia (ANC less than 0.5\*10\^9 cells/L)
Time frame: 21 days (Cycle 1 of chemotherapy treatment)
Incidence of Febrile Neutropenia
Incidence of febrile neutropenia by duraton within each cycle and across all cycles. Febrile neutropenia is defined as oral temperature greater than or equal 38.3°C while having an Absolute Neutrophil Count \< 0.5\*10\^9 cells/L (both measured on the same day)
Time frame: 21 weeks/ 6 cycles
Number of Days of Fever
Number of days of fever by cycle. Fever is defined as oral temperature greater than or equal to 38.3°C.
Time frame: 21 weeks/ 6 cycles
Depth of Absolute Neutrophil Count Nadir
Depth of Absolute Neutrophil Count Nadir, defined as the patient's lowest Absolute Neutrophil Count in cycle 1
Time frame: Cycle 1/ 21 days
Time to Absolute Neutrophil Count Recovery
Time to Absolute Neutrophil Count recovery, defined as the time in days from Absolute Neutrophil Count nadir until the patient's Absolute Neutrophil Count increases to more or equal to 2\*10\^9 cells/L after the nadir in cycle 1
Time frame: Cycle 1/ 21 days
Frequency of Infections
Frequency of infections by cycle and across all cycles
Time frame: 21 Weeks/ 6 cycles
Incidence of Hospitalizations Due to Febrile Neutropenia
Incidence of hospitalizations due to Febrile Neutropenia
Time frame: 21 Weeks/ 6 cycles
The study population consisted of women of 18 years or older with histologically proven breast cancer who were eligible for neoadjuvant or adjuvant treatment with TAC chemotherapy. The study was aimed to randomize a total of 192 patients in approximately 65 centers worldwide.
| Milestone | EP2006 | EP2006 + Neupogen | Neupogen + EP2006 | Neupogen |
|---|---|---|---|---|
| Started | 54 | 55 | 55 | 54 |
| Treated cycle 1 ep2006 | 53 | 54 | 0 | 0 |
| Treated cycle 1 neupogen | 0 | 0 | 55 | 52 |
| Treated cycle 2 ep2006 | 52 | 0 | 55 | 0 |
| Treated cycle 2 neupogen | 0 | 52 | 0 | 51 |
| Treated cycle 3 ep2006 | 51 | 51 | 0 | 0 |
| Treated cycle 3 neupogen | 0 | 0 | 54 | 51 |
| Treated cycle 4 ep2006 | 51 | 0 | 50 | 0 |
| Treated cycle 4 neupogen | 0 | 51 | 0 | 50 |
| Treated cycle 5 ep2006 | 46 | 49 | 0 | 0 |
| Treated cycle 5 neupogen | 0 | 0 | 48 | 50 |
| Treated cycle 6 ep2006 | 45 | 0 | 48 | 0 |
| Treated cycle 6 neupogen | 0 | 49 | 0 | 49 |
| Completed | 45 | 49 | 48 | 47 |
| Not completed | 9 | 6 | 7 | 7 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 |
| Withdrew: Physician decision | 1 | 1 | 3 | 0 |
| Withdrew: Withdrawal by subject | 5 | 3 | 3 | 2 |
| Withdrew: Other reason | 2 | 2 | 0 | 4 |
Mean duration of severe neutropenia, defined as the mean number of consecutive days with Grade 4 neutropenia (ANC less than 0.5\*10\^9 cells/L)
| Days | EP2006 + EP2006 & Neupogen | Neupogen + Neupogen & EP2006 |
|---|---|---|
| Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy | 1.17 ± 1.11 | 1.2 ± 1.02 |
Incidence of febrile neutropenia by duraton within each cycle and across all cycles. Febrile neutropenia is defined as oral temperature greater than or equal 38.3°C while having an Absolute Neutrophil Count \< 0.5\*10\^9 cells/L (both measured on the same day)
| participants | EP2006 | EP2006 + Neupogen | Neupogen + EP2006 | Neupogen | Total |
|---|---|---|---|---|---|
| Cycle 1 - 0 Days duration | 50 | 49 | 54 | 51 | 204 |
| Cycle 1 - 1 Day duration | 2 | 3 | 0 | 0 | 5 |
| Cycle 1 - 2 Days duration | 0 | 0 | 1 | 0 | 1 |
| Cycle 2 - 0 Days duration | 52 | 51 | 55 | 51 | 209 |
| Cycle 2 - 1 Day duration | 0 | 1 | 0 | 0 | 1 |
| Cycle 3 - 0 Days duration | 51 | 51 | 54 | 51 | 207 |
| Cycle 4 - 0 Days duration | 51 | 51 | 50 | 50 | 202 |
| Cycle 5 - 0 Days duration | 45 | 48 | 48 | 50 | 191 |
| Cycle 5 - 1 Day duration | 0 | 1 | 0 | 0 | 1 |
| Cycle 6 - 0 Days duration | 43 | 48 | 48 | 49 | 188 |
| Cycle 6 - 1 Day duration | 1 | 1 | 0 | 0 | 2 |
| All Cycles - 0 Days duration | 49 | 46 | 54 | 51 | 200 |
| All Cycles - 1 Day duration | 3 | 6 | 0 | 0 | 9 |
| All Cycles - 2 Days duration | 0 | 0 | 1 | 0 | 1 |
Number of days of fever by cycle. Fever is defined as oral temperature greater than or equal to 38.3°C.
| participants | EP2006 | EP2006 + Neupogen | Neupogen + EP2006 | Neupogen | Total |
|---|---|---|---|---|---|
| Cycle 1 - No | 39 | 41 | 42 | 46 | 168 |
| Cycle 1 - Yes | 1 | 4 | 2 | 0 | 7 |
| Cycle 2 - No | 36 | 43 | 44 | 46 | 169 |
| Cycle 2 - Yes | 4 | 2 | 0 | 0 | 6 |
| Cycle 3 - No | 40 | 44 | 44 | 45 | 173 |
| Cycle 3 - Yes | 0 | 1 | 0 | 1 | 2 |
| Cycle 4 - No | 40 | 44 | 43 | 46 | 173 |
| Cycle 4 - Yes | 0 | 1 | 1 | 0 | 2 |
| Cycle 5 - No | 40 | 44 | 43 | 45 | 172 |
| Cycle 5 - Yes | 0 | 1 | 1 | 1 | 3 |
| Cycle 6 - No | 39 | 44 | 44 | 46 | 173 |
| Cycle 6 - Yes | 1 | 1 | 0 | 0 | 2 |
Depth of Absolute Neutrophil Count Nadir, defined as the patient's lowest Absolute Neutrophil Count in cycle 1
| 10^9 cells/L | EP2006 + EP2006 & Neupogen | Neupogen + Neupogen & EP2006 | Total |
|---|---|---|---|
| Depth of Absolute Neutrophil Count Nadir | 0.808 ± 1.3694 | 0.744 ± 1.2906 | 0.776 ± 1.3278 |
Time to Absolute Neutrophil Count recovery, defined as the time in days from Absolute Neutrophil Count nadir until the patient's Absolute Neutrophil Count increases to more or equal to 2\*10\^9 cells/L after the nadir in cycle 1
| Days | EP2006 + EP2006 & Neupogen | Neupogen + Neupogen & EP2006 | Total |
|---|---|---|---|
| Time to Absolute Neutrophil Count Recovery | 2.0 (0 to 6) | 2.0 (0 to 4) | 2.0 (0 to 6) |
Frequency of infections by cycle and across all cycles
| participants | EP2006 + Neupogen | EP2006 & Neupogen + Neupogen & EP2006 | Total |
|---|---|---|---|
| Cycle 1 - No | 102 | 104 | 206 |
| Cycle 1 - Yes | 1 | 3 | 4 |
| Cycle 2 - No | 100 | 102 | 202 |
| Cycle 2 - Yes | 3 | 5 | 8 |
| Cycle 3 - No | 102 | 107 | 209 |
| Cycle 3 - Yes | 1 | 0 | 1 |
| Cycle 4 - No | 101 | 104 | 205 |
| Cycle 4 - Yes | 2 | 3 | 5 |
| Cycle 5 - No | 101 | 106 | 207 |
| Cycle 5 - Yes | 2 | 1 | 3 |
| Cycle 6 - No | 102 | 106 | 208 |
| Cycle 6 - Yes | 1 | 1 | 2 |
| All Cycles - No | 96 | 97 | 193 |
| All Cycles - Yes | 7 | 10 | 17 |
Incidence of hospitalizations due to Febrile Neutropenia
| participants | EP2006 | EP2006 + Neupogen | Neupogen + EP2006 | Neupogen | Total |
|---|---|---|---|---|---|
| No | 50 | 50 | 55 | 51 | 206 |
| Yes | 2 | 1 | 0 | 1 | 4 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EP2006 | — | 6/53 (11.3%) | 50/53 (94.3%) |
| EP2006 + Neupogen | — | 4/54 (7.4%) | 51/54 (94.4%) |
| Neupogen + EP2006 | — | 1/55 (1.8%) | 52/55 (94.5%) |
| Neupogen | — | 3/52 (5.8%) | 50/52 (96.2%) |
| Event | EP2006 | EP2006 + Neupogen | Neupogen + EP2006 | Neupogen |
|---|---|---|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 3/53 | 4/54 | 1/55 | 1/52 |
| AnaemiaBlood and lymphatic system disorders | 0/53 | 0/54 | 0/55 | 1/52 |
| DiarrhoeaGastrointestinal disorders | 0/53 | 0/54 | 0/55 | 1/52 |
| LeukopeniaBlood and lymphatic system disorders | 1/53 | 0/54 | 0/55 | 0/52 |
| EmbolismVascular disorders | 1/53 | 0/54 | 0/55 | 0/52 |
| Hypertensive crisisVascular disorders | 1/53 | 0/54 | 0/55 | 0/52 |
| Event | EP2006 | EP2006 + Neupogen | Neupogen + EP2006 | Neupogen |
|---|---|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 41/53 | 44/54 | 43/55 | 43/52 |
| NauseaGastrointestinal disorders | 29/53 | 33/54 | 32/55 | 37/52 |
| AstheniaGeneral disorders | 20/53 | 28/54 | 32/55 | 28/52 |
| Bone painMusculoskeletal and connective tissue disorders | 13/53 | 20/54 | 19/55 | 19/52 |
| FatigueGeneral disorders | 17/53 | 9/54 | 11/55 | 13/52 |
| Decreased AppetiteMetabolism and nutrition disorders | 8/53 | 4/54 | 3/55 | 13/52 |
| DiarrhoeaGastrointestinal disorders | 5/53 | 11/54 | 13/55 | 8/52 |
| AnaemiaBlood and lymphatic system disorders | 6/53 | 5/54 | 4/55 | 11/52 |
| VomitingGastrointestinal disorders | 9/53 | 10/54 | 10/55 | 9/52 |
| NeutropeniaBlood and lymphatic system disorders | 5/53 | 7/54 | 6/55 | 6/52 |
The safety set consists of all patients who received at least one dose of study drug and had at least one post-baseline safety assessment
| Age, Continuous(years) | EP2006 | EP2006 + Neupogen | Neupogen + EP2006 | Neupogen | Total |
|---|---|---|---|---|---|
| Mean | 51.5 ± 11.16 | 47.5 ± 11.64 | 49.7 ± 11.05 | 46.9 ± 10.91 | 48.9 ± 11.26 |
| Sex: Female, Male(Participants) | EP2006 | EP2006 + Neupogen | Neupogen + EP2006 | Neupogen | Total |
|---|---|---|---|---|---|
| Female | 53 | 54 | 55 | 52 | 214 |
| Male | 0 | 0 | 0 | 0 | 0 |
The record gives a start of Dec 2011, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Filgrastim